Search Within

Benjamin Francis Nulsen

Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
Groups
  1. Breast Medicine Service (7)
  2. Department of Medicine (7)
  3. Solid Tumor Oncology Division (7)
  4. Survivorship Research (7)
  5. Cardiology (5)
  6. Division of Subspecialty Medicine (5)

More Groups

People
  1. Maura Dickler (8)
  2. Clifford Hudis (7)
  3. Heather Mcarthur (5)
  4. Richard Steingart (5)
  5. Chau Dang (4)
  6. Larry Norton (4)

More People

Years
  1. 2012 (1)
  2. 2011 (2)
  3. 2009 (4)
  4. 2008 (1)
Publications
  1. Cancer Research (3)
  2. Journal of Clinical Oncology (3)
  3. Breast Cancer Research and Treatment (1)
  4. Clinical Cancer Research (1)
Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (3)
  3. Springer (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Journal Article

    Rugo, H. S.; Jo Chien, A.; Franco, S. X.; Stopeck, A. T.; Glencer, A.; Lahiri, S.; Arbushites, M. C.; Scott, J.; Park, J. W.; Hudis, C.; more...
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save
  • Impact of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue on breast MRI
    Meeting Abstract

    Goldfarb, S. B.; King, V.; Sung, J.; Pike, M.; Nulsen, B.; Jozefara, J.; Hudis, C.; Morris, E.; Dickler, M.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer
    Meeting Abstract

    Dickler, M. N.; McArthur, H. L.; Nulsen, B.; Patil, S.; Sealey, J.; Laragh, J.; Merali, C.; Steingart, R.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
    Journal Article

    Morris, P. G.; Dickler, M.; Mcarthur, H. L.; Traina, T.; Sugarman, S.; Lin, N.; Moy, B.; Come, S.; Godfrey, L.; Nulsen, B.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H.; Rugo, H.; Nulsen, B.; Traina, T.; Patil, S.; Zhou, Q.; Steingart, R.; Dang, C.; Park, J.; Moasser, M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Dickler, M.; Franco, S.; Stopeck, A.; Ma, W.; Nulsen, B.; Lyandres, J.; Melisko, M.; Lahiri, S.; Arbushites, M.; Koehler, M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
    Meeting Abstract

    Morris, P. G.; Dickler, M. N.; McArthur, H. L.; Traina, T. A.; Nulsen, B.; Steingart, R. M.; Rugo, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save